CIA
NBIX icon

Concurrent Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Concurrent Investment Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,203
Closed -$304K – 1055
2024
Q1 		$304K Sell
2,203
-316
-13% -$43.2K 0.01% 671
2023
Q4 		$332K Buy
+2,519
New +$290K 0.02% 621

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Concurrent Investment Advisors's NBIX Position: Q2 2024 in Review

Concurrent Investment Advisors sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 2,203 shares — an estimated $304K sold.

Concurrent Investment Advisors first reported a position in NBIX in Q4 2023 and held it in 2 quarters. The position peaked at $332K in Q4 2023. 594 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

  • Concurrent Investment Advisors reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
  • Concurrent Investment Advisors sold 2,203 Neurocrine Biosciences shares in Q2 2024, an estimated $304K.
  • Concurrent Investment Advisors first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 2 quarters.
  • Concurrent Investment Advisors's Neurocrine Biosciences position peaked at $332K in Q4 2023.
  • 594 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on Concurrent Investment Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.